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Yong Tang1†, Fenghua Liu1†, Chunning Zheng2, Shaochuan Sun2* and Yingsheng Jiang2Correction
After the publication of this work [1], we noticed that we
had incorrectly used the term ‘OGX-011’. All instances
of OGX-011 in the manuscript should be changed to
‘ASO-CLU’, apart from the last paragraph in the Intro-
duction section which should remain as published.
We also noticed in the first sentence of the second
paragraph of the Materials and methods section we mis-
takenly stated that OGX-011 (ASO-CLU) was purchased
from OncoGenex Technologies. As ASO-CLU is cur-
rently in the clinical testing phase, it is not available for
sale from OncoGenex Technologies. The corrected sen-
tence should read:
ASO-CLU was acquired from OncoGenex Technologies.
We apologise to the readers and OncoGenex Tech-
nologies for this oversight and any negative effects that
may have resulted from it.
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